The economic value of childhood varicella vaccination in France and Germany

Value in Health

Volumn 8, Issue 3, 2005, Pages 209-222

  Coudeville, Laurent ^a   Brunot, Alain ^a   Szucs, Thomas D ^b   Dervaux, Benoit ^a,c  

^a UNIV LILLE   (France)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c CRESGE   (France)

Author keywords

Children vaccination; Economic evaluation; Model; Varicella

Indexed keywords

CHICKENPOX VACCINE; MEASLES MUMPS RUBELLA VACCINE;

ARTICLE; CHICKENPOX; CHILD; COST BENEFIT ANALYSIS; COST CONTROL; DRUG EFFICACY; ECONOMIC ASPECT; FRANCE; GERMANY; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; METHODOLOGY; MORBIDITY; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; SOCIOECONOMICS; VACCINATION; VIRUS TRANSMISSION;

EID: 22544435490     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2005.04005.x     Document Type: Article

References (45)

1. Takahashi M, Otsuka T, Okuno Y, et al. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974;2:1288-90.
2. Barker L, Luman E, Zhao Z, et al. National, state, urban area vaccination coverage levels among children aged 19-35 months-United States, 2001. MMWR 2002;51:664-6.
3. Banz K, Wagenpfeil S, Neiss A, et al. The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine 2003;21:1256-67.
4. Beutels P, Clara R, Tormans G, et al. Costs and benefits of routine varicella vaccination in German children. J Infect Dis 1996;174(Suppl. 3):S335-41.
5. Brisson M, Edmunds WJ. Varicella vaccination in England and Wales: cost-utility analysis. Arch Dis Child 2003;88:862-9.
6. Coudeville L, Paree F, Lebrun T, et al. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 1999;17:142-51.
7. Diez Domingo J, Ridao M, Latour J, et al. A cost benefit analysis of routine varicella vaccination in Spain. Vaccine 1999;17:1306-11.
8. Brisson M, Edmunds WJ. The cost-effectiveness of varicella vaccination in Canada. Vaccine 2002; 20:1113-25.
9. Getsios D, Caro JJ, Caro G, et al. Instituting a routine varicella vaccination program in Canada: an economic evaluation. Pediatr Infect Dis J 2002; 21:542-7.
10. Scuffham PA, Lowin AV, Burgess MA. The cost-effectiveness of varicella vaccine programs for Australia. Vaccine 1999;18:407-15.
11. Scuffham P, Devlin N, Eberhart-Phillips J, et al. The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule. Soc Sci Med 1999;49:763-79.
12. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994;271:375-81.
13. Huse DM, Meissner HC, Lacey MJ, et al. Childhood vaccination against chickenpox: an analysis of benefits and costs. J Pediatr 1994;124: 869-74.
14. Burnham BR, Wells TS, Riddle JR. A cost-benefit analysis of a routine varicella vaccination program for United States Air Force Academy cadets. Mil Med 1998;163:631-4.
15. Brisson M, Edmunds WJ. Epidemiology of varicella-zoster virus in England and Wales. J Med Virol 2003;70(Suppl. 1):S9-14.
16. Halloran ME, Cochi SL, Lieu TA, et al. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol 1994;140:81-104.
17. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. Oxford: Oxford University Press, 1991.
18. Meyer PA, Seward JF, Jumaan AO, et al. Varicella mortality: trends before vaccine licensure in the United States, 1970-1994. J Infect Dis 2000;182: 383-90.
19. Rawson H, Crampin A, Noah N. Deaths from chickenpox in England and Wales 1995-7: analysis of routine mortality data. BMJ 2001;323:1091-3.
20. Sentinelles. Surveillance épidémiologique du réseau sentinelles-Janvier-Décembre 2001: Sentinelles. 2001. WWW document: Available from http://rhone.b3e.jussieu.fr/senti/php/navigation/accueil/ [accessed January 2003].
21. Brisson M, Edmunds WJ, Gay NJ, et al. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect 2000; 125:651-69.
22. Vessey SJ, Chan CY, Kuter BJ, et al. Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacy. J Pediatr 2001;139:297-304.
23. Sharrar RG, LaRussa P, Galea SA, et al. The post-marketing safety profile of varicella vaccine. Vaccine 2000;19:916-23.
24. Izurieta HS, Strebel PM, Blake PA. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA 1997;278: 1495-9.
25. Black S, Shinefield H, Ray P, et al. Postmarketing evaluation of the safety and effectiveness of varicella vaccine. Pediatr Infect Dis J 1999;18: 1041-6.
26. Grenfell BT, Anderson RM. The estimation of age-related rates of infection from case notifications and serological data. J Hyg (Lond) 1985;95:419-36.
27. Wutzler P, Färber I, Wagenffeill S, et al. Seroprevalence of varicella-zoster virus in the German population. Vaccine 2002;20:121-4.
28. Siedler A, Hermann M, Schmitt HJ, et al. Consequences of delayed measles vaccination in Germany. Pediatr Infect Dis J 2002;21:826-30.
29. INVS. Mesure de la couverture vaccinale en France - Bilan des outils et méthodes en l'an 2000: INVS; 2001. WWW document: Available from http://www.invs.sante.fr/publications/default.htm [accessed January 2003].
30. Nolan T, McIntyre P, Roberten D, et al. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Vaccine 2002;21:281-9;
31. 1999; 1;17-33.
32. Clements DA. Modified varicella-like syndrome. Infect Dis Clin North Am 1996;10:617-29.
33. Walter EB, Simmons SS, Bland CL, et al. Modified varicella-like syndrome in children previously vaccinated with live attenuated measles, mumps, rubella and varicella vaccine. Pediatr Infect Dis J 1997;16:626-7.
34. Galil K, Fair E, Mountcastle N, et al. Younger age at vaccination may increase risk of varicella vaccine failure. J Infect Dis 2002;186:102-5.
35. Evans C, Tavakoli M, Crawford B. Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal. Health Care Manag Sci 2004;7:43-9.
36. Hanslik T, Boëlle PY, Schwarzinger M, et al. Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination. Vaccine 2003;21:3614-22.
37. Coudeville L, Brunot L, Dervaux L. Childhood vaccination against varicella in France: an economic evaluation of different strategies. In: ISPOR, 6th Annual European Congress; 2003, 9-11 November 2003, Barcelona, Spain; 2003.
38. Thiry N, Beutels P, Van Damme P, et al. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 2003; 21:13-38.
39. Brouwer WB, Koopmanschap MA. On the economic foundations of CEA. Ladies and gentlemen, take your positions! J Health Econ 2000;19:439-59.
40. Coudeville L, Brunot A, Giaquinto C, et al. Varicella vaccination in italy: an economic evaluation of different scenarios. Pharmacoeconomics 2004; 22:839-55.
41. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 2002; 287:606-11.
42. Krause PR, Klinman DM. Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children. Nat Med 2000;6:451-4.
43. Jumaan A, Yu O, Bohlke K, et al. Varicella and Herpes Zoster Incidence before and after varicella vaccine licensure, 1992-2001. In: ICAAC; 2003; Chicago, Illinois, 14-17 September 2003; 2003.
44. Gershon AA. The current status of live attenuated varicella vaccine. Arch Virol Suppl 2001;17:1-6.
45. Levy-Bruhl D, Pebody R, Veldhuijzen I, et al. ESEN: a comparison of vaccination programmes-Part three: measles mumps and rubella. Euro Surveill 1998;3:115-9.